Myriad Genetics Inc (NASDAQ: MYGN) suffers from extremely meaningful negative changes in investment behavior: negative upside/downside volume developed, and its shorter term price trend turned down.
Recent meaningful negative changes in fundamentals have impacted Myriad Genetics Inc (NASDAQ: MYGN): the consensus estimate for December, 2024 decreased significantly, and the consensus estimate for December, 2025 decreased significantly.
In light of these highly negative signals we are reviewing our current Overall Rating of D. We would continue to view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, MYGN is expected to continue to be a modest Value Builder.
Myriad Genetics has a current Value Trend Rating of D (Negative). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Myriad Genetics has a very low Appreciation Score of 10 but a slightly positive Power Rating of 65, triggering the Negative Value Trend Rating.
Recent Price Action
On 4/4/24, Myriad Genetics Inc (NASDAQ: MYGN) stock declined slightly by -0.4%, closing at $20.22. NORMAL trading volume accompanied the decline. Relative to the market the stock has been strong over the last nine months but has declined -5.9% during the last week.
Be the first to comment